Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Delanzomib | Delanzomib, also known as CEP-18770, is An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB. Uses: Proteasome inhibitors. Synonyms: CEP18770; CEP 18770; CEP-18770; Delanzomib. CAS No. 847499-27-8. Molecular formula: C21H28BN3O5. Mole weight: 413.27. |  |
| Delanzomib | Delanzomib (CEP-18770) is a potent and orally active chymotrypsin-like activity of the proteasome inhibitor with an IC50 of 3.8 nM. Delanzomib inhibits NF-?B activity, induces cancer cell apoptotic, and has strong antiangiogenic and anti-cancer activities[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CEP-18770. CAS No. 847499-27-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10454. |  |
| Delanzomib | Delanzomib is an orally active proteasome inhibitor. Delanzomib has been shown to down-modulate NF-κB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis. Group: Biochemicals. Alternative Names: [ (1R) -1- [ [ (2S, 3R) -3-Hydroxy-1-oxo-2- [ [ (6-phenyl-2-pyridinyl) carbonyl] amino] butyl] amino] -3-methylbutyl] boronic Acid; CEP 18770; CIP 18770; CT 47098; NPH 007098; [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic Acid. Grades: Highly Purified. CAS No. 847499-27-8. Pack Sizes: 5mg. US Biological Life Sciences. |  Worldwide |
| (2S, 3R) -3-Hydroxy-2- (6-phenylpicolinamido) butanoic Acid | (2S, 3R) -3-Hydroxy-2- (6-phenylpicolinamido) butanoic Acid is an intermediate in the synthesis of Delanzomib (D230710), an orally active proteasome inhibitor. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 25mg. US Biological Life Sciences. | Worldwide |
| N- [ (1S, 2R) -1- [ [ [ (1R) -1- [ (3aS, 4S, 6S, 7aR) -Hexahydro-3a, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl] -3-methylbutyl] amino] carbonyl] -2-hydroxypropyl] -6-phenyl-2-pyridinecarboxamide | N- [ (1S, 2R) -1- [ [ [ (1R) -1- [ (3aS, 4S, 6S, 7aR) -Hexahydro-3a, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl] -3-methylbutyl] amino] carbonyl] -2-hydroxypropyl] -6-phenyl-2-pyridinecarboxamide is an intermediate in the synthesis of Delanzomib (D230710), an orally active proteasome inhibitor. Group: Biochemicals. Alternative Names: N- [ (1S, 2R) -1- [ [ [ (1R) -1- [ (3AS, 4S, 6S, 7aR) -hexahydro-3a, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl] -3-methylbutyl] amino] carbonyl] -2-hydroxypropyl] -6-Phenyl-2-pyridinecarboxamide. Grades: Highly Purified. CAS No. 847494-64-8. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
Our database is helping our users find suppliers everyday.
